NEW YORK, NY / ACCESSWIRE / March 22, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
Tyme Technologies, Inc. (TYME)
Class Period: March 14, 2018 - January 18, 2019
Lead Plaintiff Deadline: March 29, 2019
Join the action: https://www.zlk.com/pslra-1/tyme-technologies-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, Tyme Technologies, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme's public statements were materially false and misleading at all relevant times.
To learn more about the Tyme Technologies, Inc. class action contact email@example.com.
General Electric Company (GE)
Class Period: December 27, 2017 - October 29, 2018
Lead Plaintiff Deadline: April 2, 2019
Join the action: https://www.zlk.com/pslra-1/general-electric-company-loss-form?wire=3
About the lawsuit: During the class period, General Electric Company allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the design and technology of GE Power's flagship gas turbines were structurally flawed as they were plagued with an oxidation problem that caused the blades in the H-Class gas turbines to fail; (ii) GE Power's goodwill was materially overstated, in large part because of such structural issues; (iii) the Company lacked adequate internal and financial controls; and (iv) as a result of the foregoing, Defendant's public statements were materially false and/or misleading and/or lacked a reasonable basis.
To learn more about the General Electric Company class action contact firstname.lastname@example.org.
Vanda Pharmaceuticals Inc. (VNDA)
Class Period: November 4, 2015 - February 11, 2019
Lead Plaintiff Deadline: April 26, 2019
Join the action: https://www.zlk.com/pslra-1/vanda-pharmaceuticals-inc-loss-form?wire=3
About the lawsuit: Vanda Pharmaceuticals Inc. allegedly made materially false and/or misleading statements during the class period and/or failed to disclose that: (1) Vanda was engaged in a fraudulent scheme in which it promoted the off-label use of Fanapt and Hetlioz; (2) Vanda was fraudulently receiving drug reimbursements from the government by abusing Medicare, Medicaid, and Tricare programs; (3) as a result of the scheme, Vanda faced legal action from the government; (4) Vanda's promotional materials for Fanapt and Hetlioz were false and misleading, garnering regulatory scrutiny from the U.S. Food and Drug Administration; and (5) as a result, defendants' statements about Vanda's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
To learn more about the Vanda Pharmaceuticals Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: